Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. - Wikidata - wikimedia - TriplyDB

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

http://www.wikidata.org/entity/Q46942082

about

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma High-grade glioma management and response assessment-recent advances and current challenges Relationship and interactions of curcumin with radiation therapy The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Recurrent Glioblastoma: Where we stand Bevacizumab for glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Circulating glioma biomarkers Lessons learned from the bevacizumab experience Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Recent advancements in multimodality treatment of gliomas Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme Inhibition of SUR1 decreases the vascular permeability of cerebral metastases.Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Improving the radiosensitivity of radioresistant and hypoxic glioblastoma.Angiogenic inhibition in high-grade gliomas: past, present and future.Normalization of the vasculature for treatment of cancer and other diseases.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.PET/MRI for neurologic applications.Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Bevacizumab for acute neurologic deterioration in patients with glioblastoma.Pros and cons of current brain tumor imaging Calcification in high grade gliomas treated with bevacizumab.Safety of anticoagulation use and bevacizumab in patients with glioma.Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

P2860

Q24632791-042E9444-7D10-488A-8CF5-D5B3303C5BB9 Q26740664-A9D821C3-9C0B-4B23-8294-BA3D6F386258 Q26746150-57F0245F-1345-4E90-91A4-CF8482C0DB59 Q26752321-AC88DEBE-5703-4ED6-8880-9DEC9AF1CE30 Q26765042-AA13429B-E5F6-4142-828F-6B29902B9B05 Q26776307-A94B3EBF-1ED5-41B7-983F-3E98CF844083 Q26822717-321CDCCF-F930-46DA-82D5-791743DE1150 Q26824086-6395558E-D647-45C5-BADB-785416DF6914 Q26830329-C9517CB0-6DA4-4BFA-B5F2-513C749E8FD5 Q26852509-9A889E38-8E38-4A95-9110-48DF8EA73AE3 Q26853308-0BA5F767-F905-412E-80B7-E817E72B2B2C Q26995698-08B58357-B1A9-4F44-9CDB-CB79B3A65497 Q27001560-0B74B77F-3668-4EEE-B917-9C9792D9A46D Q27001724-5D588EF6-0A35-4A3F-A42F-6AEE7C3FEFA3 Q27011298-92D795DF-2395-4B40-801B-06B8CAE9D1E9 Q27021470-63A3B531-E9A2-4BD8-9AA6-05625B52CE03 Q28073057-8D0D5D4C-4288-4D01-9284-FE2FAA2B4BEF Q28487568-A22E5CFD-8A2C-4C22-9996-CFC2A1C442F4 Q28828676-F39F8DB5-A456-47DB-AB8B-4801F5505140 Q30273936-4B556C4A-E252-490C-8548-EEB485622DDE Q30301304-9EF2669F-9FF5-4630-B05A-AA539B76C4D3 Q30417015-EBCC987F-B4A1-4092-ADA7-A5A45D42193A Q30427266-74D04B20-3643-49B0-B57F-3E6D44928907 Q30439565-1C8C62EC-FA3D-4C2F-A8BB-23A7603E36AF Q30452219-BB62A841-6650-4687-AF3A-7089608E300A Q30455596-E0B405FD-0E37-4160-8241-854D3BD4DE9E Q30471456-7502C915-042A-4E9B-AA1B-18E5D3A9DB5E Q30493217-81ED9B61-9893-4767-8DE5-69E988D18D4C Q30577115-EB912083-F814-4B0F-B874-200EE61AEC30 Q30607148-2DE38E50-2EF2-4B11-94EB-0B9D2B7E3A1E Q30668763-1727F305-22C8-4D2D-8419-757F86ECB181 Q30708866-757B4AC8-DDAC-49D5-B83C-8642F6F05175 Q30744946-C77E565D-A845-44F3-A49E-2BE379092C7F Q30764736-6B0DEB6F-D22F-490F-9A4D-C1D136C50AB2 Q30797166-EA17C459-BBF6-453A-8383-CD00544AE849 Q30838127-A3F72E1D-B38E-42CA-BA18-48A60981E89F Q30860126-7A8229CF-36AE-4C7F-9ECF-1B672EF1759C Q30943748-A957A346-CE5D-4FEC-B9A2-B9C405D7B973 Q31153632-96A05CAA-67DA-45A7-8332-73F276F00421 Q33365902-FDD5FC7F-4ED0-4C3A-9405-BD0ABA65339A

P2860

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

http://www.wikidata.org/entity/Q46942082

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@en

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@nl

type

label

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@en

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@nl

prefLabel

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@en

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@nl

P1433

Q46942082-EFB0BB6A-DE2A-49AE-84B4-4CA0F6EFD6FB

P1476

Q46942082-66FA0F2A-3DC0-409F-8052-F5525F4F9B2F

P2093

Q46942082-13212B69-991F-49D9-9D19-B6A948D8453A

Q46942082-1B36FD4A-4417-4D6C-A78D-56417F1E0B10

Q46942082-61359B86-182A-4A4C-A9EA-81CADB9C22A5

Q46942082-71E1C585-1BDB-43A4-80D4-B0A9ACFAE05D

Q46942082-7B6690CC-5BDE-43D4-8472-DD278EB308AE

Q46942082-8C3E9F20-181C-4638-A01C-267CA8D7FAC1

Q46942082-9CA420CB-24B9-412B-BEB2-7A0758C0D10F

Q46942082-D52565AB-52A0-4892-A8CC-0396A658B268

Q46942082-E584C2D4-9D90-4487-AF85-422F3DFE9DF3

P304

Q46942082-22A331A0-943C-4A62-9488-2B8EA0BC8090

P31

Q46942082-DB140FCC-E05B-4ADF-A0F5-127BD8699A16

P356

Q46942082-A2A869E3-EE63-4E3C-896C-73A63EDCFF6F

P407

Q46942082-14DAEDC8-1A23-4119-922F-3297B43A811B

P433

Q46942082-16EBC057-9D0E-44D4-9600-D89770601413

P478

Q46942082-CBB44F56-3052-4395-A725-3B27B3148205

P50

Q46942082-152DC1D0-82E2-4C98-913C-3D954FD321D0

Q46942082-4D7F9F4E-5A39-4E39-930B-437D53322DDA

Q46942082-5F787A43-E039-4868-877A-592386A887C1

Q46942082-7F4FCD1F-9EE2-4EDB-8043-FF678AEA7302

Q46942082-99FA6AD1-B019-48E0-AA7B-1D7C99A3AE60

Q46942082-9E526AA7-1158-4814-B437-3CE7EA369465

P577

Q46942082-D6D5F47E-4CC3-4529-8701-210FA4AAFCAA

P698

Q46942082-0212EA6D-44B4-461B-B97C-B81440C936FA

P921

Q46942082-787A710C-8231-4647-8A3E-D06EC920C570

P356

JCO.2007.12.2440

P1433

Journal of Clinical Oncology

P1476

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

@en

P2093

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jennifer A Quinn

http://www.w3.org/2001/XMLSchema#string

Jennifer Marcello

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

John Sampson

http://www.w3.org/2001/XMLSchema#string

Leighann Bailey

http://www.w3.org/2001/XMLSchema#string

Melissa Wagner

http://www.w3.org/2001/XMLSchema#string

Sith Sathornsumetee

http://www.w3.org/2001/XMLSchema#string

P304

4722-4729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.12.2440

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17947719

http://www.w3.org/2001/XMLSchema#string

P921